XML 74 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Arrangements - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
Jan. 31, 2018
Dec. 31, 2017
Jul. 31, 2017
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Research and development           $ 10,208 $ 10,124 $ 6,704
Sales           40,122 39,807 39,498
Accrued and other current liabilities   $ 10,427       10,427 10,274  
Other Noncurrent Liabilities   11,117       11,117 8,514  
Amortization expense for intangible assets           3,200 3,800 $ 4,800
AstraZeneca                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Upfront and milestone payments     $ 1,600          
Payments to Acquire Intangible Assets   250 750          
Research and development           2,350    
Contingent Payments Collaborative Arrangement     6,150          
Total Consideration Collaborative Arrangement     8,500          
AstraZeneca | Future Regulatory Milestones [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contingent Payments Collaborative Arrangement     2,050          
AstraZeneca | Future Sales-Based Milestones [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contingent Payments Collaborative Arrangement     $ 4,100     4,000    
AstraZeneca | Forecast                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Payments to Acquire Intangible Assets       $ 100 $ 400      
AstraZeneca | Lynparza                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Accrued and other current liabilities   $ 100       100    
Amortization expense for intangible assets           $ 4    
Finite-Lived Intangible Assets, Remaining Amortization Period           11 years    
AstraZeneca | Lynparza | Forecast                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contingent Payments Collaborative Arrangement         100      
Sales         $ 250      
AstraZeneca | Subsequent Event                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contingent Payments Collaborative Arrangement $ 70              
Bayer AG | Future Sales-Based Milestones [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contingent Payments Collaborative Arrangement           $ 775    
Bayer AG | Adempas                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Contingent Payments Collaborative Arrangement             350  
Sales           $ 500 500  
Other Noncurrent Liabilities             350  
Amortization expense for intangible assets             $ 50